Mitochondria as an easy target to oxidative stress events in Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 430-438

  Reale, Marcella ^a   Pesce, Mirko ^a   Priyadarshini, Medha ^b   Kamal, Mohammad A ^c   Patruno, Antonia ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b ALIGARH MUSLIM UNIVERSITY   (India)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Mitochondria; Oxidative stress; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

PARKIN; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE;

APOPTOSIS; ARTICLE; DOPAMINERGIC NERVE CELL; HUMAN; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NERVE CELL NECROSIS; NERVE DEGENERATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DEPHOSPHORYLATION;

EID: 84862528681     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792875     Document Type: Article

References (106)

1. Thomas, B.; Beal, M.F. Parkinson's disease. Hum. Mol. Gen., 2007, 2, R183-R194.
2. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39, 889-909.
3. Olanow, C.W. The pathogenesis of cell death in Parkinson's disease. Mov. Disord., 2007, 22, S335-S342.
4. Mattson, M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol., 2000, 1, 120-129.
5. Schapira, A.H.; Gegg, M. Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis., 2011, 2011, 159160.
6. Schapira, A.H. Mitochondria in the etiology of Parkinson's disease. Handb. Clin. Neurol., 2007, 83, 479-491.
7. Schapira, A.H. Mitochondrial pathology in Parkinson's disease. Mt. Sinai J. Med., 2011, 78(6), 872-881.
8. Sulzer, D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci., 2007, 30, 244-250.
9. Zhou, C.; Huang, Y.; Przedborski, S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. NY Acad. Sci., 2008, 1147, 93-104.
10. Kanthasamy, A.; Jin, H.; Mehrotra, S.; Mishra, R.; Kanthasamy, A.; Rana, A. Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease. Neurotoxicology, 2010, 31(5), 555-561.
11. Patten, D.A.; Germain, M.; Kelly, M.A.; Slack, R.S. Reactive oxygen species: stuck in the middle of neurodegeneration. J. Alzheimers Dis., 2010, 20(Suppl 2), S357-S367.
12. Gómez, A.; Ferrer, I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J. Neurosci. Res., 2009, 87(4), 1002-1013.
13. Liberatore, G.T.; Jackson-Lewis, V.; Vukosavic, S.; Mandir, A.S.; Vila, M.; McAuliffe, W.G.; Dawson, V.L.; Dawson, T.M.; Przedborski, S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 1999, 5, 1354-1355.
14. Przedborski, S.; Chen, Q.; Vila, M.; Giasson, B.I.; Djaldatti, R.; Vukosavic, S.; Souza, J.M.; Jackson-Lewis, V.; Lee, V.M.; Ischiropoulos, H. Oxidative post-translational modifications of alpha-synuclein in the 1- methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem., 2001, 76, 637-640.
15. Jenner, P. Oxidative Stress in Parkinson's Disease. Ann. Neurol., 2003, 53(Suppl 3), S26-S38.
16. Tsika, E.; Ischiropoulos, H.; Malkus, K.A. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol. Neurodegener., 2009, 4, 24.
17. Devasagayam, T.P.; Tilak, J.C.; Boloor, K.K.; Sane, K.S.; Ghaskadbim, S.S.; Lele, R.D. Free radicals and antioxidants in human health: current status and future prospects. J. Assoc. Phys. Ind., 2004, 52, 794-804.
18. Fridovitch, I. Superoxide radical and superoxide dismutases. Ann. Rev. Biochem., 1995, 64, 97-112.
19. Pacher, P.; Beckman, J.S.; Liaudet, S. Nitric oxide and peroxynitrite in health and disease. Physiol Rev., 2007 87, (1), 315-424.
20. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T.D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39, 44-84.
21. Dröge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82, 47-95.
22. Reiter, C. D.; Teng, R. J.; Beckman, J. S. Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J. Biol. Chem., 2000, 275(42), 32460-32466.
23. Olas, B.; Nowak, P.; Wachowicz, B. Resveratrol protects against peroxynitrite-induced thiol oxidation in blood platelets. Cell Mol. Biol. Lett., 2004, 9(4A), 577-587.
24. Fahn, S.; Cohen, G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol., 1992, 32, 804-812.
25. Dexter, D.; Carter, C.; Agid, F. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet, 1986, 8507, 639-640.
26. Singh, S.; Dikshit, M. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res. Rev., 2007, 54, 233-250.
27. Azad, N.; Vallyathan, V.; Wang, L.; Tantishaiyakul, V.; Stehlik, C.; Leonard, S.S.; Rojanasakul, Y. S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J. Biol. Chem., 2006, 281, 34124-34134.
28. Hardingham, G.E.; Lipton, S.A. Regulation of neuronal oxidative and nitrosative stress by endogenous protective pathways and disease processes. Antiox. Redox Signal., 2011, 14(8), 1421-1424.
29. Mohr, S.; Zech, B.; Lapetina, E.G.; Brune, B. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem. Biophys. Res. Commun., 1997, 238, 387-391.
30. Alam, Z.I.; Jenner, A.; Daniel, S.E.; Lees, A.J.; Cairns, N., Marsden, C.D.; Jenner, P.; Halliwell, B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8- hydroxyguanine levels in substantia nigra. J. Neurochem., 1997, 69(3), 1196-1203.
31. Szabo, C.; Ischiropoulos, H.; Radi, R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov., 2007, 6, 662-680.
32. Dawson, V.L.; Dawson, T.M. Nitric oxide neurotoxicity. J. Chem. Neuroanatomy, 1996, 3-4, 179-190.
33. Esteves, A.R.; Arduino, D.M.; Swerdlow, R.H.; Oliveira, C.R.; Cardoso, S.M. Dysfunctional mitochondria uphold calpain activation: contribution to Parkinson's disease pathology. Neurobiol. Dis., 2010, 3, 723-730.
34. Tsang, A.H.K.; Chung, K.K.K. Oxidative and nitrosative stress in Parkinson's disease. Biochim. Biophys. Acta, 2009, 1792, 643-650.
35. Miyazaki, I.; Asanuma, M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med. Okayama, 2008, 62(3), 141-150.
36. Ischiropoulos, H.; Duran, D.; Horwitz, J. Peroxynitrite-mediated inhibition of DOPA synthesis in PC12 cells. J. Neurochem., 1995, 65, 2366-2372.
37. Gow, A.; Duran, D.; Thom, S.R.; Ischiropoulos, H. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration. Arch. Biochem. Biophys., 1996, 333(1), 42-48.
38. Hirsch, E.C.; Brandel, J.P.; Galle, P.; Javoy-Agid, F.; Agid, Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem., 1991, 56, 446-451.
39. Castro, L.; Demicheli, V.; Tórtora, V.; Radi, R. Mitochondrial protein tyrosine nitration. Free Radic. Res., 2011, 45(1), 37-52.
40. Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J., 2009, 417, 1-13.
41. Henchcliffe, C.; Flint Beal, M. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Prac. Neurol., 2008, 4, 600-609.
42. Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol., 2003, 552, 335-344.
43. Starkov, A.A. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann. NY Acad. Sci., 2008, 1147, 37-52.
44. Manfredi, G.; Beal, M.F. The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol., 2000, 10, 462-472.
45. DiMauro, S.; Schon, E.A. Mitochondrial disorders in the nervous system. Ann. Rev. Neuroscience, 2008, 31, 91-123.
46. Lin, M.T.; Flint Beal, M. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006, 443, 787-795.
47. Schapira, A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol., 2008, 7, 97-109.
48. Keeney, P.M.; Xie, J.; Capaldi, R.A.; Bennett, J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci., 2006, 26, 5256-5264.
49. Fato, R.; Bergamini, C.; Bortolus, M.; Maniero, A.L.; Leoni, S.; Ohnishi, T.; Lenaz, G. Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen species. Biochim. Biophys. Acta, 2009, 1787, 384-392.
50. Fato, R.; Bergamini, C.; Leoni, S.; Strocchi, P.; Lenaz, G. Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem. Res., 2008, 33, 2487-2501.
51. Clementi, E.; Brown, G.C.; Feelisch, M.; Moncada, S. Persistent inhibition of cell respiration by nitric oxide: crucial role of Snitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. USA, 1998, 95, 7631-7636.
52. Schapira, A.H.V.; Cooper, J.M.; Dexter, D.; Jenner, P.; Clark, J.B.; Marsden, C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 1989, 1(8649), 1269.
53. Hartley, A.; Cooper, J.M.; Schapira, A.H. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res., 1993, 627, 349-353.
54. Jenner, P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol. Scand., 1993, 87, 6-13.
55. Bresgen, N.; Jaksch, H.; Lacher, H.; Ohlenschläger, I.; Uchida, K.; Eckl, P.M. Iron-mediated oxidative stress plays an essential role in ferritin-induced cell death. Free Radic. Biol. Med., 2010, 48(10), 1347-1357.
56. Oakley, A.E.; Collingwood, J.F.; Dobson, J.; Love, G.; Perrott, H.R.; Edwardson, J.A.; Elstner, M.; Morris, C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. J. Neurol., 2007, 68(21), 1820-1825.
57. Cooke, M.S.; Evans, M.D.; Dizdaroglu, M.; Lunec, J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB, 2003, 17, 1195-1214.
58. Zhang, J.; Perry, G.; Smith, M.A.; Robertson, D.; Olson, S.G.; Doyle G.; Graham, D.G.; Montine, T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol., 1999, 154, 1423-1429.
59. Simon, D.K.; Lin, M. T.; Zheng, L.; Liu, G-J.; Ahn, C.H.; Kim, L.M.; Beal, M.F.; Johns, D. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol. Aging, 2004, 25(1), 71-81.
60. Linnane, A.W.; Marzuki, S.; Ozawa, T.; Tanaka, M. Mitochondrial DNA, mutations as an important contributor to ageing and degenerative diseases. Lancet, 1989, 1, 642-645.
61. Khrapko, K.; Vijg, J. Mitochondrial DNA mutations and aging: devils in the details? Trends Genet., 2009, 25, 91-98.
62. Ciechanover, A. The ubiquitin proteolytic system. From a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology, 2006, 66(1) S7-S19.
63. Davies, K.J. Degradation of oxidized proteins by the 20S proteasome. Biochimie, 2001, 83(3-4), 301-310.
64. Uehara, T.; Nakamura, T.; Yao, D.; Shi, Z.Q.; Gu, Z.; Ma, Y.; Masliah, E.; Nomura, Y.; Lipton, S.A. S-nitrosylated proteindisulphide isomerase links protein misfolding to neurodegeneration, Nature, 2006, 441, 513-517.
65. Thomas, K.J.; McCoy, M.K.; Blackinton, J.; Beilina, A.; van der Brug, M.; Sandebring, A.; Miller, D.; Maric, D.; Cedazo-Minguez, A.; Cookson, M.R. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet., 2011, 20(1), 40-50.
66. LaVoie, M.J.; Ostaszewski, B.L.; Weihofen, A.; Schlossmacher, M.G.; Selkoe, D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med., 2005, 11, 1214-1221.
67. Winklhofer, K.F.; Henn, I.H.; Kay-Jackson, P.C.; Heller, U.; Tatzelt, J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones, J. Biol. Chem., 2003, 278, 47199-47208.
68. Chung, K.K.; Thomas, B.; Li, X.; Pletnikova, O.; Troncoso, J.C.; Marsh, L.; Dawson, V.L.; Dawson, T.M. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science, 2004, 304, 1328-1331.
69. Yao, D.; Gu, Z.; Nakamura, T.; Shi, Z.Q.; Ma, Y.; Gaston, B.; Palmer, L.A.; Rockenstein, E.M.; Zhang, Z.; Masliah, E.; Uehara, T.; Lipton, S.A. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. USA, 2004, 101, 10810-10814.
70. Palacino, J.J.; Sagi, D.; Goldberg, M.S.; Krauss, S.; Motz, C.; Wacker, M.; Klose, J.; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem., 2004, 279, 18614-18622.
71. Piccoli, C.; Sardanelli, A.; Scrima, R.; Ripoli, M.; Quarato, G.; D'Aprile, A; Bellomo, F.; Scacco, S.; Michele, G.; Filla, A.; Iuso, A.; Boffoli, D.; Capitanio, N.; Papa, S. Mitochondrial respiratory dysfunction in familiar Parkinsonism associated with PINK1 mutation. Neurochem. Res., 2008, 33(12), 2565-2574.
72. Gautier, C.A.; Kitada, T.; Shen, J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. USA, 2008, 105(32), 11364-11369.
73. Silvestri, L.; Caputo, V.; Bellacchio, E.; Atorino, L.; Dallapiccola, B.; Valente, E.M.; Casari, G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet., 2005, 14, 3477-3492.
74. Wang, H.L.; Chou, A.H.; Wu, A.S.; Chen, S.Y.; Weng, Y.H.; Kao, Y.C.; Yeh, T.H.; Chu, P.J.; Lu CSPARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim. Biophys. Acta, 2011, 1812(6), 674-684.
75. Devi, L.; Raghavendran, V.; Prabhu, B.M.; Avadhani, N.G.; Anandatheertha-varada, H.K. Mitochondrial import and accumulation of alpha- synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem., 2008, 283, 9089-9100.
76. Haavik, J.; Almas, B.; Flatmark, T. Generation of reactive oxygen species by tyrosine hydroxylase: A possible contribution to the degeneration of Dopaminergic neurons? J. Neurochem., 1997, 68, 328-332.
77. Thomas, M.P.; Chartrand, K.; Reynolds, A.; Vitvitsky, V.; Banerjee, R.; Gendelman, H.E. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J. Neurochem., 2007, 100, 503-519.
78. Taira, T.; Saito, Y.; Niki, T.; Iguchi-Ariga, S.M.; Takahashi, K.; Ariga, H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep., 2004, 5, 213-218.
79. Martinat, C.; Shendelman, S.; Jonason, A.; Leete, T.; Beal, M.F.; Yang, L.; Floss, T.; Abeliovich, A. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol., 2004, 2, e327.
80. Smith, W.W.; Pei, Z.; Jiang, H.; Moore, D.J.; Liang, Y.; West, A.B.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. USA, 2005, 102, 18676-18681.
81. Berman, S.B.; Hastings, T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem., 1999, 73(3), 1127-1137.
82. Delsite, R.L.; Rasmussen, L.J.; Rasmussen, A.K.; Kalen, A.; Goswami, P.C.; Singh, K.K. Mitochondrial impairment is accompanied by impaired oxidative DNA repair in the nucleus. Mutagenesis, 2003, 18(6), 497-503.
83. Khan, N.L.; Jain, S.; Lynch, J.M.; Pavese, N.; Abou-Sleiman, P.; Holton, J.L.; Healy, D.G.; Gilks, W.P.; Sweeney, M.G.; Ganguly, M.; Gibbons, V.; Gandhi, S.; Vaughan, J.; Eunson, L.H.; Katzenschlager, R.; Gayton, J.; Lennox, G.; Revesz, T.; Nicholl, D.; Bhatia, K.P.; Quinn, N.; Brooks, D.; Lees, A.J.; Davis, M.B.; Piccini, P.; Singleton, A.B.; Wood, N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 2005, 128(Pt 12), 2786-2796.
84. Kim, S.T.; Chang, J.W.; Choi, J.H.; Kim, S.W.; Hwang, O. Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuro- melanin and oxidative damage in the nigrostriatal system. J. Neurochem., 2005, 95, 89-98.
85. Ly, J.D.; Grubb, D.R.; Lawen, A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis: an update. Apoptosis, 2003, 8, 115-128.
86. Schapira, A.H. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim. Biophys. Acta, 1999, 1410, 159-170.
87. Brown, J.M.; Yamamoto, B.K. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol. Ther., 2003, 99, 45-53.
88. Choi, H.J.; Kim, S.W.; Lee, S.Y.; Hwang, O. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J. Neurochem., 2003, 86, 143-152.
89. Nagatsu, T. Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem., 1995, 30, 15-35.
90. Nagatsu, I.; Ichinose, H.; Sakai, M.; Titani, K.; Suzuki, M.; Nagatsu, T. Immunocytochemical localization of GTP cyclohydrolase I in the brain, adrenal gland, and liver of mice. J. Neural Transm. Gen. Sect., 1995, 102, 175-188.
91. Kumer, S.C.; Vrana, K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem., 1996, 67, 443-462.
92. Chen, X.; Xu, L.; Radcliffe, P.; Sun, B.; Tank, A.W. Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons. Mol. Pharmacol., 2008, 3(6), 1816-1828.
93. Dunkley, P.R.; Bobrovskaya, L.; Graham, M.E.; von Nagy-Felsobuki, E.I.; Dickson, P.W. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochemistry, 2004, 91, 1025-1043.
94. Haycock, J.W. Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. J. Biol. Chem., 1990, 265(20), 11662-11691.
95. Fossom, L.H.; Sterling, C.R.; Tank, A.W. Regulation of tyrosine hydroxylase gene transcription rate and tyrosine hydroxylase mRNA stability by cyclic AMP and glucocorticoid. Mol. Pharmacol., 1992, 42(5), 898-908.
96. Ahn, J.-H.; Kim, Y.; Kim, H-S.; Greengard, P.; Nairn, A.C. Protein Kinase c-dependent dephosphorylation of tyrosine hydroxylase requires the B56d heterotrimeric form of protein phosphatase 2A. PLoS ONE, 2011, 6(1), e26292.
97. Kirsch, M.; Korth, H.G.; Stenert, V.; Sustmann, R.; de Groot, H. The autoxidation of tetrahydrobiopterin revisited. Proof of superoxide formation from reaction of tetrahydrobiopterin with molecular oxygen. J. Biol. Chem., 2003, 278(27), 24481-24490.
98. Tiefenbacher, C.P.; Chilian, W.M.; Mitchell, M.; DeFily, D.V. Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin. Circulation, 1996, 94, 1423-1429.
99. Nakamura, K.; Bindokas, V.P.; Kowlessur, D.; Elas, M.; Milstien, S.; Marks, J.D.; Halpern, H.J.; Kang, U.J. Tetrahydrobiopterin Scavenges Superoxide in Dopaminergic Neurons. J. Biol. Chem., 2001, 276(37), 34402-34407.
100. Delgado-Esteban, M.; Almeida, A.; Medina, J.M. Tetrahydrobiopterin deficiency increases neuronal vulnerability to hypoxia. J. Neurochem., 2002, 82(5), 1148-1159.
101. Ihlemann, N.; Rask-Madsen, C.; Perner, A.; Dominguez, H.; Hermann, T.; Køber, L.; Torp-Pedersen, C. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am. J. Physiol. Heart Circ. Physiol., 2003, 285(2), H875-H882.
102. Ramsey, A.J.; Fitzpatrick, P.F. Effects of phosphorylation on binding of catecholamines to tyrosine hydroxylase: Specificity and thermodynamics. Biochemistry, 2000, 39, 773-778.
103. Ramsey, A.J.; Fitzpatrick, P.F. Effects of phosphorylation of serine-40 of tyrosine hydroxylase in binding of catecholamines-Evidence for a novel regulatory mechnanism. Biochemistry, 1998, 37, 8980-8986.
104. Staal, R.G.; Mosharov, E.V.; Sulzer, D. Dopamine neurons release transmitter via a flickering fusion pore. Nat. Neurosci., 2004, 7(4), 341-346.
105. Caudle, W.M.; Richardson, J.R.; Wang, M.Z.; Taylor, T.N.; Guillot, T.S.; McCormack, A.L.; Colebrooke, R.E.; Di Monte, D.A.; Emson, P.C.; Miller, G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci., 2007, 27(30), 8138-8148.
106. Alerte, T.N.M.; Akinfolarin, A.A.; Friedrich, E.E.; Mader, S.A.; Hong, C-S.; Ruth G., Perez, R.G. α-Synuclein aggregation alters tyrosine hydroxylase phosphorilation and immunoreactivity: lessons from viral trasduction of knockout mice. Neurosci. Lett., 2008, 435(1), 24-29.